NYSEMKT: AMPEAmpio Pharmaceuticals Inc Stock
$0.22-0.08 (-26.67%)
Updated Mar 17, 2023
AMPE Price
$0.22
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$0.06
52 Week High
$0.66
P/E
-0.44x
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$20.34M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.36
Operating Cash Flow
-$21M
Beta
1.19
Next Earnings
Mar 27, 2023
Ex-Dividend
N/A
Next Dividend
N/A
AMPE Overview
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. It is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. The company's product pipeline includes Ampion, which is in phase III clinical trial, is an intra-articular injection for the treatment of osteoarthritis of the knee. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AMPE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AMPE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AMPE is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
AMPE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more AMPE due diligence checks available for Premium users.
Be the first to know about important AMPE news, forecast changes, insider trades & much more!
AMPE News
Valuation
AMPE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.44x
Industry
16.18x
Market
21.81x
AMPE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0x
Industry
4.75x
AMPE's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.4M
Profit Margin
0%
AMPE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$18.8M
Liabilities
$5.0M
Debt to equity
0.36
AMPE's short-term assets ($18.32M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AMPE's short-term assets ($18.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AMPE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AMPE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.9M
Investing
$0.0
Financing
$0.0
AMPE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
Ampio Pharmaceuticals Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.